1Sem.
Such companies should be valued according to the pipeline and not the fundamentals. I am rather keen on Biontech at the moment.
••
@Reinecke If you are judging by the pipeline, and a realistic pipeline at that: Then Novo (! sic) or Amgen. Certainly not Biontech. They make all their sales with corona vaccines, and everything else so far is science fiction that hasn't even found its way into a Phase 3 trial.... See Curevac/Heidelberg. They've been in business even longer, but this business is difficult...
••
@Gomerdoc He has Amgen and if one of the 8 Sience Fiction products works, Biontec will quickly be at 500. Thanks to Corona, liquidity is no longer a problem.
••
@Reinecke and as soon as that happens: Amgen buys Biontech 😉
••
••